Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Phase 3 KEYLYNK-006 Study of Pembrolizumab plus Olaparib versus Pembrolizumab plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous Non-Small-Cell Lung Cancer
J Thorac Oncol 2024 Nov 07;[EPub Ahead of Print], JE Gray, M Schenker, MA Nahit Şendur, V Leonova, D Kowalski, T Kato, R Orlova, J Chih-Hsin Yang, A Langleben, A Pilz, A Ungureanu, MP Mak, Flavia De Angelis, H Aggarwal, Z Zimmer, B Zhao, M Shamoun, TM KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.